{"id":3504,"date":"2025-11-18T09:13:36","date_gmt":"2025-11-18T09:13:36","guid":{"rendered":"https:\/\/neurosas.org\/strategic-intelligence\/?page_id=3504"},"modified":"2026-09-14T08:51:53","modified_gmt":"2026-09-14T08:51:53","slug":"microglia-inflammation-and-alzheimers-disease","status":"publish","type":"page","link":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/","title":{"rendered":"Microglia, Inflammation and Alzheimer\u2019s Disease"},"content":{"rendered":"

Challenge Workshop<\/span><\/h2>\n

October 11-15, 2026<\/span><\/h4>\n

 <\/p>\n

Director: Bart De Strooper<\/span><\/strong><\/h5>\n

UK Dementia Research Institute at University College London, London, UK & Katholieke Universiteit Leuven, Belgium<\/p>\n

Co-Director: Pierre Magistretti<\/span><\/strong><\/h5>\n

EPFL, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Switzerland<\/p>\n

 <\/p>\n

Faculty:<\/span><\/strong><\/p>\n

David Gate,<\/strong><\/span> Northwestern University Feinberg School of Medicine, Chicago, USA<\/p>\n

Rosa Chiara Paolicelli,<\/strong> <\/span>University of Lausanne, Switzerland<\/p>\n

Jonathan Kipnis,<\/strong><\/span> Washington University in St. Louis, USA<\/p>\n

Emanuela Pasciuto,<\/strong><\/span> University of Antwerp, Belgium<\/p>\n

Soyon Hong,<\/strong><\/span> University College London, UK<\/p>\n

Vijay Kumar Kuchroo, <\/strong><\/span>Harvard Medical School, Boston, USA<\/p>\n

Pierre Magistretti,<\/strong><\/span> EPFL, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Switzerland<\/p>\n

Bart De Strooper,<\/strong><\/span> UK Dementia Research Institute at University College London, London, UK & Katholieke Universiteit Leuven, Belgium<\/p>\n

 <\/p>\n

Immunity, inflammation, and energy metabolism are central to Alzheimer\u2019s Disease, yet their roles shift dramatically over time and across brain regions. This Challenge Workshop, with world leaders in the field, asks when immune responses become maladaptive, where they operate within plaque and Tau-rich niches, and how microglia, astrocytes, and peripheral cells drive the transition from protection to pathology. Understanding these dynamics opens the door to interventions at the nexus of immunity, inflammation and energy metabolism that restore balance rather than suppress biology.<\/p>\n

 <\/p>\n

Bart De Strooper<\/span><\/p>\n

Critical transitions that shape the development of Alzheimer\u2019s disease<\/em><\/p>\n

The course of Alzheimer\u2019s disease is often portrayed as a simple progression in which amyloid beta deposition leads to Tau aggregation and, subsequently, to neuronal loss. An alternative view holds that the disorder advances through a series of biologically defined stages, separated by critical inflection points. At each threshold, accumulating stress exceeds the capacity of cellular systems to maintain equilibrium, resulting in abrupt, qualitative changes in cellular and circuit behaviour. The intervals between these inflection points can be understood as transition phases during which altered cellular states spread across anatomically and functionally distinct tissue domains. These domains form a patchwork that gradually involves vulnerable cognitive networks. Among these transitions, the onset of self-reinforcing Tau pathology represents a decisive turning point. By focusing on thresholds and timing rather than a linear cascade, this framework provides a coherent explanation for the frequent mismatch between pathological load and clinical symptoms. It also highlights the common structure underlying familial and sporadic forms of the disease and emphasises the slow erosion of homeostatic resilience as a defining feature of Alzheimer\u2019s disease.<\/p>\n

 <\/p>\n

Vijay Kumar Kuchroo<\/span><\/p>\n

Immune checkpoint molecules as guardians of microglial homeostasis and function<\/em><\/p>\n

Among the cells that influence the course of Alzheimer\u2019s disease (AD), microglia\u2014which are the resident immune cells of the central nervous system (CNS)\u2014play a pivotal role in sensing, engulfing, and removing pathological proteins, as well as regulating neuronal health. Since microglia often become dysfunctional and fail to clear toxic A\u03b2 aggregates in AD, understanding the molecular pathways that restrain or activate microglial responses is central to developing new therapeutic strategies for AD.
\nOne pathway that has recently emerged as a key regulator of immune cell activity is the immune checkpoint system. Immune checkpoints sustain immune balance by limiting activation in T cells and other immune subsets. The co-inhibitory receptor TIM-3 (T-cell immunoglobulin and mucin domain-3) is well established as a negative regulator of T cells, promoting exhaustion and impaired effector T cell responses1\u20133. TIM-3 blockade has become a major focus in cancer immunotherapy, with numerous clinical trials underway and TIM-3 is now recognized as an important regulator of myeloid cells, including macrophages and dendritic cells. Most relevant to AD, a recent genome-wide association study identified HAVCR2, the gene encoding TIM-3, as an AD susceptibility gene5. Intriguingly, within the CNS, TIM-3 expression is highly enriched in microglia, particularly as they mature into their homeostatic state. Microglia also co-express other checkpoint receptors, most notably LAG-3 (lymphocyte activation gene-3), but the functional significance of this co-expression in neurodegeneration has remained unexplored.
\nOur recent work revealed that TIM-3 is a central regulator of microglial homeostasis and function6. Selective deletion of Tim-3 in microglia converts them into a highly phagocytic, MGnD\/DAM-like state without inducing inflammation, enabling more efficient clearance of A\u03b2 plaques. In the 5xFAD AD model, microglia-specific Tim-3 deletion reduces neurotoxic plaque features and improves cognitive performance. Furthermore, TIM-3 and LAG-3 are enriched in non-phagocytic microglia, and Lag3 expression increases when Tim-3 is lost, suggesting compensatory or cooperative interactions between these checkpoint pathways6.
\nIn aging mice, 5xFAD transgenic models, and human AD datasets, we observed concurrent upregulation of TIM3 and LAG3 in microglia, with TIM3\u207aLAG3\u207a microglial populations correlating with AD neuropathologic change and dementia severity. In human APOE4 carriers (who have increased AD risk), TIM3\/LAG3 double-positive microglia are particularly enriched. These findings collectively suggest that immune checkpoint receptors play a previously unrecognized role in regulating microglial function, and that dysregulated TIM-3 and LAG-3 signalling may contribute to AD pathogenesis. Together, these observations point to a crucial immunoregulatory axis in AD involving TIM-3 and LAG-3 and will be a focus of discussion during the talks.<\/p>\n

 <\/p>\n

Jonathan Kipnis<\/span><\/p>\n

Brain clearance as a key factor in neuroimmunology<\/em><\/p>\n

Recent evidence has challenged many dogmas in neuroimmunology. Brain-derived \u2018waste\u2019 from deep within the brain is mobilized via the glymphatic system towards immunologically active brain borders, where meningeal lymphatic vessels are appropriately positioned to drain waste and antigens from the brain to the periphery. The presentation of brain-derived self-peptides at the brain\u2019s borders is critical for enabling active immunosurveillance, limiting aberrant immune reactivity, and clearing the brain of toxic compounds. Taking these novel concepts into account, we develop new therapies for neurodegenerative diseases, including lymphatic-based modifications such as genetic, pharmacological and surgical approaches.<\/p>\n

 <\/p>\n

David Gate<\/span><\/p>\n

Immune contributions to Alzheimer\u2019s disease pathogenesis and therapy<\/em><\/p>\n

The immune system plays a dynamic and complex role in Alzheimer\u2019s disease (AD), with protective and pathological contributions that evolve across disease stages. My laboratory investigates how adaptive and innate immune mechanisms intersect with neurodegeneration, focusing on T cell responses, microglial states, and their therapeutic modulation. Previously, we demonstrated that clonally expanded CD8 T cells patrol the cerebrospinal fluid (CSF) in AD patients, revealing an adaptive immune response characterized by antigen-driven clonal expansions that may influence neuroinflammation. Building on this, subsequent studies revealed CSF immune dysregulation during healthy brain aging and cognitive impairment, showing that CSF immune cells change with age and in AD, with shifts in T cell and myeloid populations that disrupt brain homeostasis. Furthermore, epigenetic dysregulation in peripheral immunity in AD was shown, highlighting chromatin accessibility changes in circulating immune cells (particularly CD8 T cells and monocytes) that are linked to genetic risk factors such as ApoE and promote inflammatory gene expression. More recent studies have also identified microglial mechanisms driving amyloid-\u03b2 clearance in immunized AD patients. Using spatial transcriptomics on brain tissue from clinical trial participants, we showed that effective amyloid removal is associated with specific microglial phenotypes that not only clear plaques but also help restore a healthier brain environment. Current research in the lab is exploring immune mechanisms in cerebral amyloid angiopathy (CAA)-related inflammation. We are applying single-cell and spatial transcriptomic approaches to dissect the interplay between microglia, vascular pathology, and peripheral immune infiltration in CAA, aiming to identify molecular drivers of inflammation and potential targets for mitigating vascular complications in AD. This work underscores the importance of timing, context, and cellular states in harnessing immunity for AD therapy.<\/p>\n

 <\/p>\n

Emanuela Pasciuto<\/span><\/p>\n

Microglia-T cell crosstalk in Alzheimer\u2019s disease: from cellular mechanisms to therapeutic implications<\/em><\/p>\n

Alzheimer\u2019s disease is often viewed through the lens of amyloid beta accumulation, Tau pathology, and neuronal dysfunction. However, disease progression is also shaped by immune transitions that alter how the brain responds to pathology over time. Microglia are central to this process, but their function is not determined by intrinsic programs alone. Increasing evidence suggests that adaptive immune cells, particularly T cells, enter the Alzheimer\u2019s disease brain and may influence whether microglial responses remain protective, become ineffective, or contribute to tissue damage. Microglia\u2013T cell crosstalk acts as a regulatory axis in Alzheimer\u2019s disease, and the timing of immune activation and early microglial priming shapes later responses to amyloid pathology. In preclinical models, we find increased infiltration of both CD4-positive and CD8-positive T cells in the Alzheimer\u2019s disease brain, together with a relationship between T cell accumulation and major histocompatibility complex class II expression on microglia. These observations support the idea that antigen presentation marks a disease-associated immune state in which microglia become positioned to communicate with adaptive immune cells.<\/p>\n

Using genetic models that selectively remove major histocompatibility complex class II from microglia, we further examine whether this pathway is required for T cell recruitment, microglial functional state, and plaque-associated responses.<\/p>\n

The therapeutic relevance of this interaction is particularly important, as several immune-based approaches now aim to harness protective regulatory T cell responses in neurodegenerative disease. Building on this concept, the talk will discuss regulatory T cell-based strategies and their effects on microglial function in preclinical models of Alzheimer\u2019s disease. Brain-directed interleukin-2 treatment modifies microglial phenotype, induces major histocompatibility complex class II expression, enhances microglial phagocytic capacity, and alters disease-related microglial transcriptional programs without broadly inducing inflammatory modules. These findings suggest that regulatory T cells may influence Alzheimer\u2019s disease progression, at least in part, by reshaping microglial responses to amyloid pathology.<\/p>\n

Together, these data support a model in which microglia\u2013T cell interactions are active regulators of disease progression rather than secondary consequences of neurodegeneration. Defining when these interactions promote resilience or dysfunction may help refine immune-based therapeutic strategies for Alzheimer\u2019s disease and other neurodegenerative disorders marked by chronic inflammation and antigen presentation.<\/p>\n

 <\/p>\n

Soyon Hong<\/span><\/p>\n

Neuroimmune control of synapse vulnerability in neurodegeneration<\/em><\/p>\n

My laboratory investigates how neuroimmune pathways shape selective synaptic and neuronal vulnerability in neurodegenerative diseases including Alzheimer\u2019s and Parkinson\u2019s diseases. Rather than viewing inflammation as a uniform downstream response to pathology, we study how microglia, astrocytes, border-associated macrophages, and peripheral immune cells detect and interpret early changes in neuronal activity, proteostasis, and tissue state. I will discuss our work on immune-mediated synapse loss, including complement- and phagocytosis-related mechanisms, astrocyte\u2013microglia signalling, and brain-border macrophage pathways that modulate microglial function and cognitive decline. Together, these studies support a model in which age-related synaptic dysfunction reflects a progressive failure of immune and glial homeostatic capacity across vulnerable neural interfaces. Understanding when these responses are protective, compensatory, or maladaptive may reveal therapeutic windows for restoring neuroimmune balance before irreversible circuit damage occurs.<\/p>\n

 <\/p>\n

Rosa Chiara Paolicelli<\/span><\/p>\n

Early-life microglial dysfunction in the pathogenesis of brain disease<\/em><\/p>\n

Microglia play essential roles in both brain physiology and pathology. It is now well established that a large proportion of genetic variants associated with an increased risk of neurodegenerative disorders are highly enriched in microglia, strongly suggesting that microglial dysfunction contributes to susceptibility to neurodegeneration. However, the precise mechanisms and developmental stages through which these risk genes influence microglial behavior and promote brain pathology remain poorly understood.
\nNotably, several microglia-associated risk genes implicated in neurodegenerative disorders are not only expressed under pathological conditions but are also highly enriched during brain development. This observation raises the intriguing possibility that genetic risk variants may critically influence microglia during sensitive developmental windows, thereby affecting the mechanisms by which these cells shape neural circuit formation and maturation, as well as myelin integrity.
\nIt is reasonable to hypothesize that the mechanisms by which microglial dysfunction confers vulnerability to brain disease should be investigated well before disease onset. By combining in vivo mouse models with ex vivo and in vitro approaches, our laboratory investigates how impaired microglial function influences brain development, leading to long-lasting alterations in neuronal function and behavior, and how disease-associated risk genes contribute to these processes. In this context, we highlight the importance of critical developmental windows and propose that microglial dysfunction during early postnatal development may be a key determinant of increased susceptibility to neurodegeneration later in life.<\/p>\n

 <\/p>\n

Pierre Magistretti<\/span><\/p>\n

Neuron\u2013glia metabolic coupling mediated by lactate: relevance for neuroenergetics, neuroplasticity and neurodegenerative diseases<\/em><\/p>\n

A tight metabolic coupling between astrocytes and neurons is a central feature of brain energy metabolism. Over the years, my lab has identified and molecularly characterised two key mechanisms of neurometabolic coupling: neuromodulator (VIP, adenosine and noradrenaline)-induced glycogenolysis in astrocytes and glutamate-stimulated aerobic glycolysis. Both processes lead to the release of lactate from astrocytes, which serves as an energy substrate for neurons as defined by the Astrocyte-Neuron Lactate Shuttle (ANLS) model.
\nSubsequent work in my lab showed that lactate also acts as a signalling molecule, enhancing NMDA receptor activity, promoting long-term memory, and activating gene expression programs linked to synaptic plasticity. Electrophysiological and behavioural studies further demonstrated that astrocytic lactate supply is activity-dependent and scales with computational demand. Recent data indicate that lactate potentiates NMDAR currents via monocarboxylate transporter (MCT)-dependent neuronal uptake, conversion to pyruvate, increased NADH, and redox-sensitive modulation of GluN2B subunits, involving CaMKII signalling.
\nRecent preclinical studies in various conditions show that pharmacological stimulation of the ANLS restores behavioural deficits present in hypometabolic conditions such as Glut1 deficiency syndrome (de Vivo disease) and Alzheimer\u2019s disease, supporting the strategy of targeting astrocytes to overcome brain hypometabolism. In preclinical models of depression, lactate was shown to exert antidepressant effects that depend on neurogenesis. Together, these findings establish lactate as a metabolic\u2013signalling nexus linking astrocyte function to neuronal computation, plasticity, and behaviour, and open new therapeutic perspectives for neurodegenerative, mood, and metabolic brain disorders.<\/p>\n","protected":false},"excerpt":{"rendered":"

Challenge Workshop October 11-15, 2026   Director: Bart De Strooper UK Dementia Research Institute at University College London, London, UK & Katholieke Universiteit Leuven, Belgium Co-Director: Pierre Magistretti EPFL, \u00c9coleRead More Microglia, Inflammation and Alzheimer\u2019s Disease<\/span><\/a><\/p>\n","protected":false},"author":42,"featured_media":2559,"parent":861,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-3504","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nMicroglia, Inflammation and Alzheimer\u2019s Disease - Neuroscience School of Advanced Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Microglia, Inflammation and Alzheimer\u2019s Disease - Neuroscience School of Advanced Studies\" \/>\n<meta property=\"og:description\" content=\"Challenge Workshop October 11-15, 2026   Director: Bart De Strooper UK Dementia Research Institute at University College London, London, UK & Katholieke Universiteit Leuven, Belgium Co-Director: Pierre Magistretti EPFL, \u00c9coleRead More Microglia, Inflammation and Alzheimer\u2019s Disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuroscience School of Advanced Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-14T08:51:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neurosas.org\/strategic-intelligence\/wp-content\/uploads\/2025\/08\/challenge-workshops-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"729\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/\",\"name\":\"Microglia, Inflammation and Alzheimer\u2019s Disease - Neuroscience School of Advanced Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/challenge-workshops-1.jpg\",\"datePublished\":\"2025-11-18T09:13:36+00:00\",\"dateModified\":\"2026-09-14T08:51:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/challenge-workshops-1.jpg\",\"contentUrl\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/challenge-workshops-1.jpg\",\"width\":1280,\"height\":729},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/microglia-inflammation-and-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Challenge Workshops\",\"item\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The Workshops\",\"item\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/challenge-workshops\\\/the-workshops\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Microglia, Inflammation and Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/#website\",\"url\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/\",\"name\":\"Neuroscience School of Advanced Studies\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/#organization\",\"name\":\"Neuroscience School of Advanced Studies\",\"url\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/NSI_logo.png\",\"contentUrl\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/NSI_logo.png\",\"width\":1135,\"height\":414,\"caption\":\"Neuroscience School of Advanced Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/neurosas.org\\\/strategic-intelligence\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Microglia, Inflammation and Alzheimer\u2019s Disease - Neuroscience School of Advanced Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Microglia, Inflammation and Alzheimer\u2019s Disease - Neuroscience School of Advanced Studies","og_description":"Challenge Workshop October 11-15, 2026   Director: Bart De Strooper UK Dementia Research Institute at University College London, London, UK & Katholieke Universiteit Leuven, Belgium Co-Director: Pierre Magistretti EPFL, \u00c9coleRead More Microglia, Inflammation and Alzheimer\u2019s Disease","og_url":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/","og_site_name":"Neuroscience School of Advanced Studies","article_modified_time":"2026-09-14T08:51:53+00:00","og_image":[{"width":1280,"height":729,"url":"https:\/\/neurosas.org\/strategic-intelligence\/wp-content\/uploads\/2025\/08\/challenge-workshops-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/","url":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/","name":"Microglia, Inflammation and Alzheimer\u2019s Disease - Neuroscience School of Advanced Studies","isPartOf":{"@id":"https:\/\/neurosas.org\/strategic-intelligence\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/neurosas.org\/strategic-intelligence\/wp-content\/uploads\/2025\/08\/challenge-workshops-1.jpg","datePublished":"2025-11-18T09:13:36+00:00","dateModified":"2026-09-14T08:51:53+00:00","breadcrumb":{"@id":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/#primaryimage","url":"https:\/\/neurosas.org\/strategic-intelligence\/wp-content\/uploads\/2025\/08\/challenge-workshops-1.jpg","contentUrl":"https:\/\/neurosas.org\/strategic-intelligence\/wp-content\/uploads\/2025\/08\/challenge-workshops-1.jpg","width":1280,"height":729},{"@type":"BreadcrumbList","@id":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/microglia-inflammation-and-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neurosas.org\/strategic-intelligence\/"},{"@type":"ListItem","position":2,"name":"Challenge Workshops","item":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/"},{"@type":"ListItem","position":3,"name":"The Workshops","item":"https:\/\/neurosas.org\/strategic-intelligence\/challenge-workshops\/the-workshops\/"},{"@type":"ListItem","position":4,"name":"Microglia, Inflammation and Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/neurosas.org\/strategic-intelligence\/#website","url":"https:\/\/neurosas.org\/strategic-intelligence\/","name":"Neuroscience School of Advanced Studies","description":"","publisher":{"@id":"https:\/\/neurosas.org\/strategic-intelligence\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neurosas.org\/strategic-intelligence\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/neurosas.org\/strategic-intelligence\/#organization","name":"Neuroscience School of Advanced Studies","url":"https:\/\/neurosas.org\/strategic-intelligence\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neurosas.org\/strategic-intelligence\/#\/schema\/logo\/image\/","url":"https:\/\/neurosas.org\/strategic-intelligence\/wp-content\/uploads\/2026\/07\/NSI_logo.png","contentUrl":"https:\/\/neurosas.org\/strategic-intelligence\/wp-content\/uploads\/2026\/07\/NSI_logo.png","width":1135,"height":414,"caption":"Neuroscience School of Advanced Studies"},"image":{"@id":"https:\/\/neurosas.org\/strategic-intelligence\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/pages\/3504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/users\/42"}],"replies":[{"embeddable":true,"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/comments?post=3504"}],"version-history":[{"count":20,"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/pages\/3504\/revisions"}],"predecessor-version":[{"id":3738,"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/pages\/3504\/revisions\/3738"}],"up":[{"embeddable":true,"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/pages\/861"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/media\/2559"}],"wp:attachment":[{"href":"https:\/\/neurosas.org\/strategic-intelligence\/wp-json\/wp\/v2\/media?parent=3504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}